Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone.
作者信息
Bloch Michael J, Basile Jan N
机构信息
Department of Internal Medicine, University of Nevada School of Medicine, and Risk Reduction Center, Saint Mary's Regional Medical Center, 645 North Arlington Street, Reno, NV 89503, USA.
出版信息
J Clin Hypertens (Greenwich). 2010 Oct;12(10):809-12. doi: 10.1111/j.1751-7176.2010.00358.x. Epub 2010 Aug 20.
Abstract
摘要
相似文献
1
Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone.血管紧张素受体阻滞剂-中性内肽酶抑制剂联合用药比单独使用血管紧张素受体阻滞剂能进一步降低血压。
J Clin Hypertens (Greenwich). 2010 Oct;12(10):809-12. doi: 10.1111/j.1751-7176.2010.00358.x. Epub 2010 Aug 20.
2
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.血管紧张素受体拮抗剂与中性内肽酶抑制剂联合使用
Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622.
3
Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy.血管紧张素受体脑啡肽酶抑制剂用于治疗高血压：心血管药物治疗中被忽视的领域。
Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):122-123. doi: 10.1093/ehjcvp/pvz005.
4
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.中性肽链内切酶抑制剂LCZ-696（沙库巴曲/缬沙坦）的药代动力学、药效学及降压作用
J Am Soc Hypertens. 2017 Jul;11(7):461-468. doi: 10.1016/j.jash.2017.04.012. Epub 2017 May 25.
5
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.联合抑制 Neprilysin 和肾素-血管紧张素系统治疗心力衰竭。
JACC Heart Fail. 2014 Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8.
6
Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.血管紧张素 II 受体-脑啡肽酶抑制剂沙库巴曲缬沙坦可改善自发性高血压大鼠的血管内皮功能障碍。
J Am Heart Assoc. 2017 Oct 17;6(10):e006617. doi: 10.1161/JAHA.117.006617.
7
Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension.选择性抑制 ACE（血管紧张素转换酶）的 C 端结构域与抑制 NEP（中性内肽酶）联合应用：高血压治疗的一种新方法。
Hypertension. 2021 Sep;78(3):604-616. doi: 10.1161/HYPERTENSIONAHA.121.17041. Epub 2021 Jul 26.
8
Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.血管紧张素-脑啡肽酶抑制通过限制足细胞损伤为糖尿病和高血压大鼠提供肾保护作用。
J Hypertens. 2020 Apr;38(4):755-764. doi: 10.1097/HJH.0000000000002326.
9
Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.沙库巴曲缬沙坦双重抑制血管紧张素受体和中性肽链内切酶在慢性收缩性心力衰竭中的应用：解读新的PARADIGM研究
Ann Pharmacother. 2015 Nov;49(11):1237-51. doi: 10.1177/1060028015593093. Epub 2015 Jul 14.
10
Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.沙库巴曲缬沙坦而非单独的肾素-血管紧张素系统抑制：难治性高血压治疗的一大进步。
J Clin Hypertens (Greenwich). 2018 Jan;20(1):65-68. doi: 10.1111/jch.13146. Epub 2017 Dec 13.
引用本文的文献
1
Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.沙库巴曲缬沙坦而非单独的肾素-血管紧张素系统抑制：难治性高血压治疗的一大进步。
J Clin Hypertens (Greenwich). 2018 Jan;20(1):65-68. doi: 10.1111/jch.13146. Epub 2017 Dec 13.
2
Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.在中国健康男性受试者中评估阿托伐他汀与新型血管紧张素受体脑啡肽酶抑制剂LCZ696之间的药物相互作用潜力。
Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):309-318. doi: 10.1007/s13318-016-0349-y.
3
Drug discovery in renin-angiotensin system intervention: past and future.肾素-血管紧张素系统干预中的药物研发：过去与未来
Ther Adv Cardiovasc Dis. 2016 Jun;10(3):118-25. doi: 10.1177/1753944716642680. Epub 2016 Apr 27.
4
Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.沙库巴曲缬沙坦（LCZ696）在中国健康受试者单剂量给药后的药代动力学、安全性和耐受性
Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):109-116. doi: 10.1007/s13318-016-0328-3.
5
How full is our antihypertensives pipeline?我们的抗高血压药物研发线进展如何？
J Pharmacol Pharmacother. 2012 Jan;3(1):7-11. doi: 10.4103/0976-500X.92492.
Zotero 插件